Advertisement

 

 

Long-Acting Antiretrovirals: Where Are We now?

Long-Acting Antiretrovirals: Where Are We now?
Author Information (click to view)

Nyaku AN, Kelly SG, Taiwo BO,


Nyaku AN, Kelly SG, Taiwo BO, (click to view)

Nyaku AN, Kelly SG, Taiwo BO,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Current HIV/AIDS reports 2017 03 16() doi 10.1007/s11904-017-0353-0

Abstract
PURPOSE OF REVIEW
Current HIV treatment options require daily use of combination antiretroviral drugs. Many persons living with HIV experience treatment fatigue and suboptimal adherence as a result. Long-acting antiretroviral drugs are being developed to expand options for HIV treatment. Here, we review the agents in development, and evaluate data from recent clinical trials. In addition, we anticipate challenges to successful widespread use of long-acting antiretrovirals.

RECENT FINDINGS
Parenteral nanosuspensions of cabotegravir and rilpivirine, and dapivirine vaginal ring are the farthest in clinical development. Long-acting modalities in earlier development stages employ drug-loaded implants, microparticles, or targeted mutagenesis, among other innovations. Long-acting antiretroviral drugs promise new options for HIV prevention and treatment, and ways to address poor adherence and treatment fatigue. Further studies will identify the long-acting agents or combinations that are suitable for routine use. Creative solutions will be needed for anticipated implementation challenges.

Submit a Comment

Your email address will not be published. Required fields are marked *

19 − 14 =

[ HIDE/SHOW ]